Search - tctmd.com

Displaying 661 - 680 of 947

Sort: Relevancy | Date

News Conference News ACC 2025

FAIR-HF2: Another IV Iron Trial Fails to Impact Hard Endpoints

L.A. McKeown

April 03, 2025

News Conference News ACC 2025

Nurses Can Be Pivotal in Post-ACS Secondary Prevention: ALLEPRE

Caitlin E. Cox

April 02, 2025

News Conference News ACC 2025

RIVAWAR: Rivaroxaban as Safe and Effective as Warfarin for LV Thrombus in MI

Michael O'Riordan

April 02, 2025

News Conference News ACC 2025

Tight Fluid Restriction Not Needed in Chronic HF Patients: FRESH-UP

Michael O'Riordan

April 01, 2025

News Conference News EHRA 2025

Sudden Cardiac Death Risk Linked to Long-term Antidepressant Use

Todd Neale

April 01, 2025

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for March 2025

Caitlin E. Cox

April 01, 2025

News Conference News ACC 2025

PCI Rebounds at 5 Years to Mostly Match CABG: Final FAME 3 Data

Caitlin E. Cox

March 31, 2025

News Conference News ACC 2025

Shelf-stable Product May Sub in for Frozen Plasma in Cardiac Surgery: FARES-II

L.A. McKeown

March 31, 2025

News Conference News ACC 2025

By 2 Years, Tricuspid TEER Reduces Hospitalizations for HF: TRILUMINATE

Michael O'Riordan

March 31, 2025

News Conference News EHRA 2025

Chronic HF Patients Needing CRT Fare Better With LBB Pacing: HeartSync-LBBP

Todd Neale

March 31, 2025

News Conference News ACC 2025

Evolut Low Risk Trial: TAVI Holds Up to Surgery at 5 Years

L.A. McKeown

March 30, 2025

News Conference News ACC 2025

More ALIGN-AR Data Bolster Potential for a Dedicated AR Device

Yael L. Maxwell

March 30, 2025

News Conference News ACC 2025

Dapagliflozin Works Well for High-Risk TAVI Patients With HF: DapaTAVI

Caitlin E. Cox

March 30, 2025

News Conference News ACC 2025

Strike Two: BHF PROTECT-TAVI Throws Cold Water on Embolic Protection

Michael O'Riordan

March 30, 2025

News Conference News EHRA 2025

Uncertainties Remain About Same-Day Discharge After AF Ablation

Todd Neale

March 30, 2025

Presentation ACC 2025

The MIGHTy-Heart Randomized Clinical Trial

Presenter: Ruth Masterson Creber

March 30, 2025

News Conference News ACC 2025

SOUL: Oral Semaglutide Bests Usual Care in High-Risk Type 2 Diabetes

Michael O'Riordan

March 29, 2025

Presentation ACC 2025

STRIDE - Semaglutide and walking capacity in people with symptomatic peripheral artery disease and type 2 diabetes

Presenter: Marc P. Bonaca

March 29, 2025

Presentation ACC 2025

Advance-HTN: Lorundrostat Efficacy and Safety in Patients with Uncontrolled Hypertension

Presenter: Luke Laffin

March 29, 2025

Presentation ACC 2025

Oral Semaglutide Reduces Cardiovascular Events in People with Type 2 Diabetes with Atherosclerotic Cardiovascular and/or Chronic Kidney Disease: Primary Results From the SOUL Randomized Trial

Presenter: Darren K. McGuire

March 29, 2025

Advertisement

FAIR-HF2: Another IV Iron Trial Fails to Impact Hard Endpoints

Nurses Can Be Pivotal in Post-ACS Secondary Prevention: ALLEPRE

RIVAWAR: Rivaroxaban as Safe and Effective as Warfarin for LV Thrombus in MI

Tight Fluid Restriction Not Needed in Chronic HF Patients: FRESH-UP

Sudden Cardiac Death Risk Linked to Long-term Antidepressant Use

TCTMD’s Top 10 Most Popular Stories for March 2025

PCI Rebounds at 5 Years to Mostly Match CABG: Final FAME 3 Data

Shelf-stable Product May Sub in for Frozen Plasma in Cardiac Surgery: FARES-II

By 2 Years, Tricuspid TEER Reduces Hospitalizations for HF: TRILUMINATE

Chronic HF Patients Needing CRT Fare Better With LBB Pacing: HeartSync-LBBP

Evolut Low Risk Trial: TAVI Holds Up to Surgery at 5 Years

More ALIGN-AR Data Bolster Potential for a Dedicated AR Device

Dapagliflozin Works Well for High-Risk TAVI Patients With HF: DapaTAVI

Strike Two: BHF PROTECT-TAVI Throws Cold Water on Embolic Protection

Uncertainties Remain About Same-Day Discharge After AF Ablation

The MIGHTy-Heart Randomized Clinical Trial

SOUL: Oral Semaglutide Bests Usual Care in High-Risk Type 2 Diabetes

STRIDE - Semaglutide and walking capacity in people with symptomatic peripheral artery disease and type 2 diabetes

Advance-HTN: Lorundrostat Efficacy and Safety in Patients with Uncontrolled Hypertension

Oral Semaglutide Reduces Cardiovascular Events in People with Type 2 Diabetes with Atherosclerotic Cardiovascular and/or Chronic Kidney Disease: Primary Results From the SOUL Randomized Trial

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content